WO2002032847A1 - Procede de purification de la pravastatine ou de son sel pharmacologiquement acceptable - Google Patents
Procede de purification de la pravastatine ou de son sel pharmacologiquement acceptable Download PDFInfo
- Publication number
- WO2002032847A1 WO2002032847A1 PCT/JP2001/009044 JP0109044W WO0232847A1 WO 2002032847 A1 WO2002032847 A1 WO 2002032847A1 JP 0109044 W JP0109044 W JP 0109044W WO 0232847 A1 WO0232847 A1 WO 0232847A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- pravastatin
- sodium
- pharmacologically acceptable
- acceptable salt
- Prior art date
Links
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 title claims abstract description 85
- 150000003839 salts Chemical class 0.000 title claims abstract description 63
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960002965 pravastatin Drugs 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000005185 salting out Methods 0.000 claims abstract description 23
- 235000002639 sodium chloride Nutrition 0.000 claims description 81
- 229960001495 pravastatin sodium Drugs 0.000 claims description 37
- -1 alkali metal salt Chemical class 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000012535 impurity Substances 0.000 claims description 21
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- 150000007522 mineralic acids Chemical class 0.000 claims description 15
- 229910052783 alkali metal Inorganic materials 0.000 claims description 14
- 150000007529 inorganic bases Chemical class 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 150000003863 ammonium salts Chemical class 0.000 claims description 9
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 6
- 239000005695 Ammonium acetate Substances 0.000 claims description 6
- 235000019257 ammonium acetate Nutrition 0.000 claims description 6
- 229940043376 ammonium acetate Drugs 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 5
- 238000009938 salting Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- 239000010410 layer Substances 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000013078 crystal Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 14
- 235000008504 concentrate Nutrition 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000035484 reaction time Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 229910017053 inorganic salt Inorganic materials 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 229940090181 propyl acetate Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000002086 displacement chromatography Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- MYXBSDASKFJGKY-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.OC.CC(O)=O MYXBSDASKFJGKY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- KLTPDYHAASMFGP-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO.CCCCCCO KLTPDYHAASMFGP-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- XKPJKVVZOOEMPK-UHFFFAOYSA-M lithium;formate Chemical compound [Li+].[O-]C=O XKPJKVVZOOEMPK-UHFFFAOYSA-M 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- GMDNUWQNDQDBNQ-UHFFFAOYSA-L magnesium;diformate Chemical compound [Mg+2].[O-]C=O.[O-]C=O GMDNUWQNDQDBNQ-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000005121 nitriding Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/60—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Definitions
- the present invention relates to a method for purifying pravastatin or a pharmacologically acceptable salt thereof by salting out.
- Pravastatin is a compound disclosed as a ⁇ MG-Go ⁇ reductase inhibitor in JP-A-57-2240 (US Pat. No. 4,346,227), and has the following formula (I)
- Pravastatin sodium is currently being marketed as a therapeutic agent for hypolipidemia (
- WO 92/1 6276 (Tokuhyo Hei 6-506 210) discloses: "An HMG-CoA reductase inhibitor characterized by using high performance liquid chromatography.
- the HMG-CoA reductase inhibitor specifically described with respect to the ⁇ Purification method '' is a fat-soluble oral pastatin and simpastatin in order to obtain a ratatotone body as a final product. This is different from pravastatin, which uses salt as the final product.
- WO 00/17182 discloses “displacement chromatography And a method of purifying an HMGG-CoA reductase inhibitor. However, after all, considering industrial production, purification using chromatography such as high performance liquid chromatography or displacement chromatography is cumbersome and impractical.
- This gazette discloses that after adjusting a culture concentrate of an HMG-CoA reductase inhibitor to pH 4.5 to 7.5 with an acid, the HMG-CoA reductase inhibitor was extracted with ethyl acetate. And then, if desired, lactonizing and crystallizing to obtain an HMG-CoA reductase inhibitor having a purity of 99.6 / o or more.
- Example 3 of this publication describes a method for isolating or purifying pravastatin, in this example, the purity of pravastatin extracted with ethyl acetate was less than 70.3%. However, after all, there is a description of purification using chromatography, and further, the purity of the finally obtained pravastatin is not described at all, and high-purity pravastatin is finally obtained. It is unknown at first whether or not.
- lovastatin which is said to be obtained with a purity of 99.6% or more, has a purity of 99.9%, as shown in the HPLC chart of the final product (Fig. 4). It is unlikely that more than 6% of the oral pastatin is obtained and is not credible.
- the purification method of the present invention is characterized by using salting-out, and is a method of adding an inorganic salt or the like to an aqueous solution to precipitate a previously dissolved substance.
- salting out purifies high molecular compounds such as protein amino acids from impurities.
- high molecular compounds such as protein amino acids
- salting out purifies high molecular compounds such as protein amino acids from impurities.
- high molecular compounds such as protein amino acids from impurities.
- salt ions used to For example, when a large amount of salt is added to an aqueous solution of a protein, the interaction between the protein molecule and the water molecule is hindered by salt ions, so that the protein is precipitated.
- HMG-CoA reductase inhibitors Many compounds other than pravastatin are known as HMG-CoA reductase inhibitors.
- atorvastatin, flupastatin, itavastatin and the like are all compounds produced by synthesis.
- lovastatin and simpastatin are produced by fermentation in the same way as pravastatin, but are produced by one-stage fermentation, but pravastatin is produced by two-stage fermentation. That is, as shown in the following formula, pravastatin sodium is produced by subjecting the precursor produced in the first stage fermentation to microbial conversion culture in the second stage.
- fermenting a bacterium produces many unpredictable impurities rather than performing a chemical reaction. Even if purification is performed in each step, it is not possible to remove all the impurities, and it is even more difficult to remove the impurities, especially in a large-scale culture for industrial production.
- "One of the key factors in producing safe and effective medicines is obtaining high-purity products. Chemical substances are synthesized from raw materials, and are produced by living organisms. Obtained by a manufacturing method such as isolating or purifying the substance, or isolating or purifying the substance produced by production using genetically modified cells, etc.
- HMG-CoA reductase inhibitors are drugs that are administered over a long period of time to effectively lower blood cholesterol, and must be particularly high-purity to minimize side effects. It is said that.
- pravastatins produced by two-step fermentation produce more impurities than simvastatin and oral pastatin produced by one-step fermentation, and thus the purification step is particularly important.
- pravastatin or a pharmacologically acceptable salt thereof is not so complicated and industrially disadvantageous as chromatography, does not impair productivity, and has high purity enough to be purified by chromatography.
- Disclosure of the invention is not so complicated and industrially disadvantageous as chromatography, does not impair productivity, and has high purity enough to be purified by chromatography.
- the present inventors have studied a method for isolating or purifying pravastatin or a pharmacologically acceptable salt thereof having a purity as high as that which can be purified by chromatography, without impairing process productivity, for many years. As a result, they have found that high purity pravastatin can be selectively precipitated by using salting out for pravastatin, which is a low molecular compound, and completed the present invention.
- Alkali metal salt refers to, for example, alkali metal halides such as lithium chloride, potassium chloride, and sodium chloride, lithium acetate, potassium acetate, sodium acetate, lithium formate, potassium formate, and sodium formate.
- Alkali metal organic oxides, salts containing alkali metals such as alkali metal inorganic oxides such as lithium nitrate, potassium nitrate, sodium nitrate, lithium sulfate, lithium sulfate, sodium sulfate, etc.
- alkaline earth metal salt means, for example, an alkaline earth metal halide such as magnesium chloride, an alkaline earth metal organic oxide such as magnesium acetate or magnesium formate, magnesium nitrate, magnesium sulfate, or the like.
- a salt containing an alkaline earth metal such as an anorekari earth metal inorganic oxide such as
- ammonium salt is, for example, an ammonium salt such as ammonium chloride, ammonium acetate, ammonium formate, ammonium nitrate, or ammonium sulfate.
- the salt used in the salting-out of the present invention is not particularly limited as long as it is generally used as a salt, but is preferably an alkali metal salt, an alkaline earth metal salt or an ammonium salt. More preferably, it is an alkali metal salt or an ammonium salt, more preferably, sodium chloride, ammonium sulfate, ammonium acetate or ammonium nitrate, and most preferably, sodium chloride.
- Pharmacologically acceptable salt '' in ⁇ Pharmacologically acceptable salt '' There is no particular limitation as long as it does not cause pharmacological side effects and is usually used as a salt, but examples thereof include alkali metal salts such as sodium salt, potassium salt, and lithium salt, calcium salts, and magnesium salts.
- Metal salts such as alkaline earth metal salts, aluminum salts, and iron salts; inorganic salts such as ammonium salts; metal salts such as aluminum salts, iron salts, zinc salts, copper salts, Eckerl salts, and cobalt salts; t-octylamine Salt, dibenzylamine salt, morpholine salt, darcosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methyldalcamine salt, guanidine salt, getylamine salt, triethylamine salt, dicyclohexylamine salt, N, N'-dibenzyl Ethylene diamine salt, black mouth, procaine salt, procaine, dietano Amine salts such as organic amines such as ruamine salts, N-benzylphenethylamine salts, piperazine salts, tetramethylammonium salts, tris (hydroxymethyl) aminoamino salts
- the salting-out method of the present invention comprises adding an inorganic salt to an aqueous solution in which pravastatin or a pharmacologically acceptable salt is dissolved or suspended, cooling the mixture, then adding pravastatin seed crystals, and re-adding.
- the cooling is carried out by precipitating the salt of pravastatin.
- the salt used for salting out may or may not have the same cation as the pharmacologically acceptable salt of pravastatin.
- the amount of the inorganic salt to be added to the aqueous solution in which the pharmacologically acceptable salt of prapastatin is dissolved or suspended is preferably 5% to 40% with respect to the amount of the above aqueous solution, most preferably. Is between 15% and 35%.
- the temperature at which an inorganic salt is added to an aqueous solution in which a pharmacologically acceptable salt of pravastatin is dissolved or suspended and heated varies depending on the type of the inorganic salt used, but is usually from 20 ° C to 60 ° C. C, and preferably 30 ° C. to 45 ° C.
- the method for purifying pravastatin or a pharmacologically acceptable salt thereof according to the present invention is characterized in that, in addition to salting-out, the power of performing a step of decomposing impurities with an inorganic base is combined, and / or The force performed by combining the steps of decomposition in each step is performed by the following method.
- the “inorganic base” used in the inorganic base decomposition of impurities is not particularly limited as long as it is used as an inorganic base in a usual reaction, and examples thereof include lithium carbonate, sodium carbonate, and potassium carbonate.
- Alkali metal carbonates Alkali metal bicarbonates such as lithium bicarbonate, sodium bicarbonate, hydrogen bicarbonate
- Alkali metal hydrides such as lithium hydride, sodium hydride, hydrogen hydride
- water Alkali metal hydroxides such as lithium oxide, sodium hydroxide and potassium hydroxide
- alkaline metal alkoxides such as lithium methoxide, sodium methoxide, sodium methoxide and potassium t-butoxide
- alkali metal hydroxides and most preferred are hydroxides Sodium.
- the step of decomposing the impurities of pravastatin or a pharmaceutically acceptable salt thereof with an inorganic base is carried out in the presence or absence (preferably, in the presence) of an inert solvent, of pravastatin or a pharmaceutically acceptable salt thereof. Is performed under the condition of giving pH10 to pH14.
- the reaction temperature and reaction time for decomposing pravastatin or its pharmacologically acceptable salt impurities with an inorganic base also depend on the pH value, but basically, the lower the reaction temperature, the longer the reaction time If the reaction temperature is high, the reaction time must be shortened.For example, the reaction temperature is -10 ° C to 110 ° C, and the reaction time is 15 minutes to 200 hours. is there.
- the preferred reaction conditions for decomposing impurities contained in the culture concentrate containing pravastatins produced by the bacteria with an inorganic base are as follows: pH is 11 to 14 (more preferably, 11 to 12). ), The reaction temperature is 40 ° C to 110 ° C (more preferably, 95 ° C to 105 ° C), and the reaction time is 2 hours to 24 hours (more preferably, 2 hours to 5 hours). Time).
- the inert solvent used to decompose pravastatin or its pharmacologically acceptable salt impurities with an inorganic base is an inert solvent that is inert to this reaction, and is usually used conveniently as a solvent.
- an aqueous acid solution such as an aqueous sulfuric acid solution is added, an organic solvent immiscible with water such as ethyl acetate is added, an organic layer containing a target compound is separated, washed with water or the like, and the solvent is distilled off.
- an aqueous acid solution such as an aqueous sulfuric acid solution is added, an organic solvent immiscible with water such as ethyl acetate is added, an organic layer containing a target compound is separated, washed with water or the like, and the solvent is distilled off.
- activated carbon to remove color
- remove activated carbon by filtration add a salt-forming reagent such as sodium methoxide, sodium ethoxide, and sodium hydroxide, and concentrate under reduced pressure using a rotary evaporator.
- pravastatin salt can be obtained.
- the “inorganic acid” commonly used in the inorganic acid decomposition of impurities is not particularly limited as long as it is usually used as an inorganic acid. Examples thereof include hydrobromic acid, hydrochloric acid, sulfuric acid, perchloric acid, Inorganic acids such as phosphoric acid and nitric acid can be mentioned, preferably phosphoric acid or sulfuric acid, and most preferably phosphoric acid.
- the step of decomposing pravastatin or a pharmaceutically acceptable salt thereof with an inorganic acid the step of decomposing pravastatin or a pharmaceutically acceptable salt thereof in the presence or absence (preferably, in the presence) of an inert solvent is performed. The reaction is performed under the condition of giving pH 2 to 5 (preferably pH 3 to 4).
- the reaction temperature and reaction time for decomposing pravastatin or its pharmacologically acceptable salt impurities with an inorganic acid also depend on the pH value, but basically, the lower the reaction temperature, the longer the reaction time If the reaction temperature is high, the reaction time must be shortened.
- the reaction temperature is 20 ° C. to 80 ° C. (preferably 40 ° C. to 60 ° C.). ), And the reaction time is 1 minute to 6 hours (preferably 5 minutes to 20 minutes).
- the inert solvent used when decomposing the impurities of pravastatin or a pharmacologically acceptable salt thereof with an inorganic acid is not particularly limited as long as it is inert to the reaction. And the same inert solvent as those used in the step of decomposing impurities.
- the target compound, pravastatin is collected from the above reaction solution according to a conventional method.
- it can be obtained by adding an organic solvent immiscible with water such as ethyl acetate, separating an organic layer containing the target compound, purifying the organic layer with water or the like, and distilling off the solvent.
- an organic solvent immiscible with water such as ethyl acetate
- separating an organic layer containing the target compound purifying the organic layer with water or the like, and distilling off the solvent.
- activated carbon to decolorize remove the activated carbon by filtration
- add a salt-forming reagent such as sodium hydroxide, sodium methoxide, sodium methoxide, and reduce the pressure with a mouth evaporator.
- the pravastatin salt can be obtained by concentration under the following conditions.
- pravastatin or a pharmacologically acceptable salt thereof may be purified as described above and then crystallized.
- a method L1 well known in the art of organic synthetic chemistry is described in Ulmann's, Encyclopedia. of Industrial Chemistry, Vol. A24, 5th edition (1993), pp. 437-505].
- pravastatin or a pharmacologically acceptable salt thereof is obtained by adding an organic solvent and water to purified pravastatin or a pharmacologically acceptable salt thereof, heating and dissolving, and inoculating the solution. Can be obtained.
- organic solvent used for crystallization examples include aliphatic hydrocarbons such as hexane and heptane; aromatic hydrocarbons such as toluene and xylene: methyl acetate, ethyl acetate, propyl acetate, and acetic acid.
- Esters such as butyl and getyl carbonate; organic acids such as acetic acid; methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, isoamyl alcohol, Alcohols such as tylene glycol, glycerin, and otanol; ketones such as acetone and methylethyl ketone; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxetane, diethylene glycol dimethinole ether Amides such as formamide, dimethylformamide, dimethylacetamide, and hexamethylphosphoric triamide; sulfoxides such as dimethinole sulfoxide; or a mixed solvent of water and one or more of the above solvents. More preferably, it is a mixed solvent of water and one or more
- low-purity brapastatin or a pharmacologically acceptable salt thereof can be obtained without using a complicated and low-productivity method such as column chromatography, which is not suitable for industrial production. Salt can be obtained.
- the pravastatin of the present invention or a pharmacologically acceptable salt thereof is used as a medicament, it is mixed with a pharmacologically acceptable diluent or the like itself or an appropriate pharmacologically acceptable agent. It can be administered orally by a lock, capsule, granule, powder, syrup or the like, or parenterally by injection or suppository.
- HPLC high performance liquid chromatography
- the aqueous layer (3) was charged into an eggplant flask (50 O ml), and concentrated under reduced pressure to about 2Z5 with an evaporator to obtain a back-extracted aqueous layer concentrate (88 ml) (content of pravastatin sodium: 19.3 g). .
- Example 1 The aqueous layer (3) was charged into an eggplant flask (50 O ml), and concentrated under reduced pressure to about 2Z5 with an evaporator to obtain a back-extracted aqueous layer concentrate (88 ml) (content of pravastatin sodium: 19.3 g).
- bravastatin sodium 78.69% according to 3 ml tH PLC (Condition A) of the back-extracted aqueous layer concentrate obtained in Reference Example 1 was subdivided into test tubes and approximately 50. Add up to C After the temperature, 0.83 g of ammonium nitrate was added, and the mixture was cooled to 38 ° C to precipitate crystals. The mixture was heated to 53 ° C, but the crystals did not dissolve. The mixture was cooled to 0 ° C and filtered. The crystals were washed with cold water to obtain pravastatin sodium salted out crystals. Purity of pravastatin sodium by HPLC (Condition A) was 93.37%. Example 7.
- 132 ml of ethyl acetate was added to 7 Om 1 of the alkali-treated solution (content of pravastatin sodium: 5.3 g), and the pH was adjusted to 5.4 with a 20% aqueous sulfuric acid solution while stirring at room temperature. After stirring and extracting at room temperature, the mixture was separated into an ethyl acetate layer 1 and an aqueous layer 1. 132 ml of ethyl acetate was added to the aqueous layer, and the mixture was extracted and separated to obtain an ethyl acetate layer.
- pravastatin sodium content 4.4 g
- Purity of pravastatin sodium by HPLC is 84.88. /. Met.
- This back-extracted aqueous layer is concentrated under reduced pressure to about 1/2 volume with an evaporator, and After adjusting the pH to 12 with a sodium aqueous solution, salting out was performed in the same manner as in Example 1 using sodium chloride to obtain a pravastatin sodium precipitated crystal.
- the purity of pravastatin sodium according to HP LC (condition A) is 99.54. /. Met.
- pravastatin sodium crystals Purity of pravastatin sodium by HPLC (Condition B) is 99.85 ° /. Met.
- 60 ml of the back-extracted aqueous layer was concentrated to about 20%, cooled to 0 ° C, and then 4 equivalents of sodium hydroxide.
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01974857A EP1327624A4 (en) | 2000-10-16 | 2001-10-15 | PROCESS FOR THE PURIFICATION OF PRAVASTATIN OR ITS PHARMACOLOGICALLY ACCEPTABLE SALT |
PL01360920A PL360920A1 (en) | 2000-10-16 | 2001-10-15 | Method of purifying pravastatin or its pharmacologically acceptable salt |
IL15515801A IL155158A0 (en) | 2000-10-16 | 2001-10-15 | A method for purification of pravastatin |
SK452-2003A SK4522003A3 (en) | 2000-10-16 | 2001-10-15 | Method of purifying pravastatin or its pharmacologically acceptable salt |
KR10-2003-7004751A KR20030043984A (ko) | 2000-10-16 | 2001-10-15 | 프라바스타틴 또는 이의 약리학적으로 허용가능한 염의정제 방법 |
BR0114680-7A BR0114680A (pt) | 2000-10-16 | 2001-10-15 | Método para a purificação de pravastatina ou de um sal farmacologicamente aceitável da mesma |
AU2001294257A AU2001294257A1 (en) | 2000-10-16 | 2001-10-15 | Method of purifying pravastatin or its pharmacologically acceptable salt |
CA002425882A CA2425882A1 (en) | 2000-10-16 | 2001-10-15 | Method of purifying pravastatin or its pharmacologically acceptable salt |
MXPA03003346A MXPA03003346A (es) | 2000-10-16 | 2001-10-15 | Metodo para la purificacion de pravastatina o una sal farmacologicamente aceptable de la misma. |
HU0303123A HUP0303123A3 (en) | 2000-10-16 | 2001-10-15 | Method of purifying pravastatin or its pharmacologically acceptable salt |
NO20031738A NO20031738L (no) | 2000-10-16 | 2003-04-15 | Fremgangsmåte for rensing av pravastatin eller dets farmakologisk akseptable salt |
US10/414,691 US20030204105A1 (en) | 2000-10-16 | 2003-04-16 | Method for purification of pravastatin or a pharmacologically acceptable salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000315255A JP2002121172A (ja) | 2000-10-16 | 2000-10-16 | プラバスタチン又はその薬理上許容される塩の精製方法 |
JP2000-315255 | 2000-10-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/414,691 Continuation-In-Part US20030204105A1 (en) | 2000-10-16 | 2003-04-16 | Method for purification of pravastatin or a pharmacologically acceptable salt thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002032847A1 true WO2002032847A1 (fr) | 2002-04-25 |
Family
ID=18794391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/009044 WO2002032847A1 (fr) | 2000-10-16 | 2001-10-15 | Procede de purification de la pravastatine ou de son sel pharmacologiquement acceptable |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030204105A1 (ja) |
EP (1) | EP1327624A4 (ja) |
JP (1) | JP2002121172A (ja) |
KR (1) | KR20030043984A (ja) |
CN (1) | CN1481352A (ja) |
AU (1) | AU2001294257A1 (ja) |
BR (1) | BR0114680A (ja) |
CA (1) | CA2425882A1 (ja) |
CZ (1) | CZ2003956A3 (ja) |
HU (1) | HUP0303123A3 (ja) |
IL (1) | IL155158A0 (ja) |
MX (1) | MXPA03003346A (ja) |
NO (1) | NO20031738L (ja) |
PL (1) | PL360920A1 (ja) |
SK (1) | SK4522003A3 (ja) |
WO (1) | WO2002032847A1 (ja) |
ZA (1) | ZA200302968B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005500307A (ja) * | 2001-06-21 | 2005-01-06 | アンドルックス ファーマスーティカルズ インコーポレーテッド | プラバスタチンを含む安定な徐放性薬剤組成物 |
US6716615B2 (en) * | 2002-02-27 | 2004-04-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase |
JP4813841B2 (ja) * | 2005-07-25 | 2011-11-09 | キユーピー株式会社 | プラバスタチンナトリウムの製造方法 |
WO2009068556A1 (en) * | 2007-11-29 | 2009-06-04 | Dsm Ip Assets B.V. | Purification of pravastatin |
CN111393432A (zh) * | 2020-04-09 | 2020-07-10 | 北京世纪迈劲生物科技有限公司 | 去甲托品醇盐析制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5058284A (ja) * | 1973-09-29 | 1975-05-21 | ||
GB1543563A (en) * | 1975-02-07 | 1979-04-04 | Glaxo Lab Ltd | Beta-lactam antibiotic in purified form |
GB2077264A (en) * | 1980-06-06 | 1981-12-16 | Sankyo Co | Ml-236b derivatives and their preparation |
EP0605230A1 (en) * | 1992-12-28 | 1994-07-06 | Sankyo Company Limited | Hexanhydronaphthalene ester derivatives, their preparation and their therapeutic uses |
JPH06256278A (ja) * | 1993-03-03 | 1994-09-13 | Nissan Chem Ind Ltd | 光学活性α−カルバモイルアルカン酸誘導体およびその製法 |
JPH0767671A (ja) * | 1993-07-06 | 1995-03-14 | Haarmann & Reimer Corp | 強酸及びその塩を添加することによる純度の低い粗生成混合物からのクエン酸の回収法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI20305A (sl) * | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
SI20070A (sl) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
US6444452B1 (en) * | 1999-11-30 | 2002-09-03 | Biogal Gyogyszergyar Rt. | Process for recovering statin compounds from a fermentation broth |
-
2000
- 2000-10-16 JP JP2000315255A patent/JP2002121172A/ja not_active Withdrawn
-
2001
- 2001-10-15 PL PL01360920A patent/PL360920A1/xx not_active Application Discontinuation
- 2001-10-15 EP EP01974857A patent/EP1327624A4/en not_active Withdrawn
- 2001-10-15 IL IL15515801A patent/IL155158A0/xx unknown
- 2001-10-15 HU HU0303123A patent/HUP0303123A3/hu unknown
- 2001-10-15 KR KR10-2003-7004751A patent/KR20030043984A/ko not_active Application Discontinuation
- 2001-10-15 CZ CZ2003956A patent/CZ2003956A3/cs unknown
- 2001-10-15 CA CA002425882A patent/CA2425882A1/en not_active Abandoned
- 2001-10-15 BR BR0114680-7A patent/BR0114680A/pt not_active IP Right Cessation
- 2001-10-15 CN CNA018206344A patent/CN1481352A/zh active Pending
- 2001-10-15 WO PCT/JP2001/009044 patent/WO2002032847A1/ja not_active Application Discontinuation
- 2001-10-15 AU AU2001294257A patent/AU2001294257A1/en not_active Abandoned
- 2001-10-15 MX MXPA03003346A patent/MXPA03003346A/es unknown
- 2001-10-15 SK SK452-2003A patent/SK4522003A3/sk unknown
-
2003
- 2003-04-15 ZA ZA200302968A patent/ZA200302968B/en unknown
- 2003-04-15 NO NO20031738A patent/NO20031738L/no not_active Application Discontinuation
- 2003-04-16 US US10/414,691 patent/US20030204105A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5058284A (ja) * | 1973-09-29 | 1975-05-21 | ||
GB1543563A (en) * | 1975-02-07 | 1979-04-04 | Glaxo Lab Ltd | Beta-lactam antibiotic in purified form |
GB2077264A (en) * | 1980-06-06 | 1981-12-16 | Sankyo Co | Ml-236b derivatives and their preparation |
EP0605230A1 (en) * | 1992-12-28 | 1994-07-06 | Sankyo Company Limited | Hexanhydronaphthalene ester derivatives, their preparation and their therapeutic uses |
JPH06256278A (ja) * | 1993-03-03 | 1994-09-13 | Nissan Chem Ind Ltd | 光学活性α−カルバモイルアルカン酸誘導体およびその製法 |
JPH0767671A (ja) * | 1993-07-06 | 1995-03-14 | Haarmann & Reimer Corp | 強酸及びその塩を添加することによる純度の低い粗生成混合物からのクエン酸の回収法 |
Non-Patent Citations (2)
Title |
---|
KAGAKU DAIJITEN HENSHUU IIN-KAI ED.: "Kagaku dai-jiten 1", KYORITSU SHUPPAN, 1 July 1963 (1963-07-01), pages 1108, XP002949756 * |
NIPPON KAGAKU-KAI ED.: "Jikken kagaku kouza, kihon sousa I", MARUZEN, 5 November 1990 (1990-11-05), pages 188, XP002949757 * |
Also Published As
Publication number | Publication date |
---|---|
CZ2003956A3 (cs) | 2003-09-17 |
MXPA03003346A (es) | 2003-06-19 |
ZA200302968B (en) | 2004-07-15 |
NO20031738D0 (no) | 2003-04-15 |
PL360920A1 (en) | 2004-09-20 |
EP1327624A1 (en) | 2003-07-16 |
AU2001294257A1 (en) | 2002-04-29 |
KR20030043984A (ko) | 2003-06-02 |
US20030204105A1 (en) | 2003-10-30 |
EP1327624A4 (en) | 2004-07-14 |
IL155158A0 (en) | 2003-10-31 |
CN1481352A (zh) | 2004-03-10 |
SK4522003A3 (en) | 2003-11-04 |
HUP0303123A3 (en) | 2004-10-28 |
HUP0303123A2 (hu) | 2004-01-28 |
CA2425882A1 (en) | 2003-04-15 |
NO20031738L (no) | 2003-06-11 |
JP2002121172A (ja) | 2002-04-23 |
BR0114680A (pt) | 2003-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003523751A (ja) | 培養液の精製方法 | |
JP3236282B1 (ja) | プラバスタチンを精製する方法 | |
WO2002032847A1 (fr) | Procede de purification de la pravastatine ou de son sel pharmacologiquement acceptable | |
WO1996033197A1 (en) | Preparation of clavulanate salts | |
JP4954421B2 (ja) | クラブラン酸塩の精製方法 | |
JP3463881B2 (ja) | プラバスタチン又はその薬理上許容される塩の単離・精製方法 | |
JP5065569B2 (ja) | 工業的に生産されたプラバスタチンナトリウム含有組成物 | |
JP3422791B2 (ja) | プラバスタチンの単離・精製方法 | |
JP3463875B2 (ja) | プラバスタチンを精製する方法 | |
US9802934B2 (en) | Process for the synthesis of (R)-praziquantel | |
CN1312814A (zh) | 制备棒酸盐类及其酯类的改进方法 | |
JP3883525B2 (ja) | プラバスタチンナトリウムの精製方法 | |
EP1673361B1 (en) | A method for the manufacture of lovastatin | |
JP5419570B2 (ja) | 2−アセチルアミノメチル−4−(4−フルオロベンジル)モルホリンの精製方法 | |
JP5397706B2 (ja) | 高純度1−ベンジル−3−アミノピロリジンの製造方法 | |
EP1452519A1 (en) | Method for the isolation and purification of pravastatin sodium | |
AU692091C (en) | Preparation of clavulanate salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CO CZ HU ID IL IN KR MX NO NZ PL RU SG SK US VN ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001974857 Country of ref document: EP Ref document number: 155158 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037004751 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-956 Country of ref document: CZ Ref document number: 407/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 525255 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4522003 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/02968 Country of ref document: ZA Ref document number: PA/a/2003/003346 Country of ref document: MX Ref document number: 2425882 Country of ref document: CA Ref document number: 200302968 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10414691 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001294257 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200300383 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037004751 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018206344 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001974857 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-956 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001974857 Country of ref document: EP |